(19) World Intellectual Property **Organization**

International Bureau



(43) International Publication Date 18 August 2005 (18.08.2005)

PCT

(10) International Publication Number WO 2005/075420 A2

C07D 207/12, (51) International Patent Classification⁷:

A61K 31/4015, A61P 11/06

(21) International Application Number:

PCT/EP2005/000874

(22) International Filing Date: 28 January 2005 (28.01.2005)

(25) Filing Language:

4

English

(26) Publication Language:

English

GB

(30) Priority Data:

0402101.0 30 January 2004 (30.01.2004)

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BHALAY, Gurdip [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB (GB). DUNSTAN, Andrew [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB (GB). GLEN, Angela [GB/GB]; 1 Mill Farm, Otten Road, Belchamp Otten, Sudbury, Suffolk CO10 7BH (GB). HOWE, Trevor, John [GB/BE]; Avenue des Capucines 40, B-1950 Kraainem (BE). MCCARTHY,

Clive [GB/CH]; Novartis AG, Lichtstrasse 35, CH-4056 Basel (CH).

(74) Agent: DRESSEL, Jürgen; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORGANIC COMPOUNDS

$$T - X - \left(\begin{matrix} H \\ C \\ H \end{matrix}\right)_{m} \left(\begin{matrix} R^{1} \\ C \\ R^{2} \end{matrix}\right)_{n} Y - \left(\begin{matrix} C \\ C \\ H \end{matrix}\right)_{p} U$$
 (I)

(57) Abstract: Compounds of formula (I) in free or salt form, wherein T, X, Y, U, R¹, R², m, n and p have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.